
HeartFlow Inc (HTFL) Stock Forecast & Price Target
HeartFlow Inc (HTFL) Analyst Ratings
Bulls say
HeartFlow is well-positioned for continued growth and has delivered strong results with 2Q26 revenues of $64.1 million, a 48% increase compared to the previous year. The company's plaque business is rapidly ramping up with the positive 2026 reimbursement implementation, which has been highly synergistic with its core FFRCT business. HeartFlow's high gross margins, potential for further margin expansion, and potential upside to estimates from new reimbursement and account adds make it a strong investment opportunity. With a robust pipeline of clinical trials and a potential doubling of its TAM to $11 billion, HeartFlow is on track for durable mid-20s revenue growth in the years to come.
Bears say
HeartFlow is currently experiencing impressive growth with both the plaque and FFRCT components driving its revenue increase. However, the company's projected deceleration in the second half of 2026 and its conservative approach in terms of guidance suggest potential concerns about its future growth potential. Additionally, while its projected 2027 revenue shows strong growth, it may still be a conservative estimate considering the company's track record of underpromising and overdelivering. Therefore, while there may be some short-term risks and potential for slower growth in the future, HeartFlow remains a strong company with promising long-term prospects.
This aggregate rating is based on analysts' research of HeartFlow Inc and is not a guaranteed prediction by Public.com or investment advice.
HeartFlow Inc (HTFL) Analyst Forecast & Price Prediction
Start investing in HeartFlow Inc (HTFL)
Order type
Buy in
Order amount
Est. shares
0 shares